Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete or Partial Responders

NCT06175000 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT06175000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06175000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete or Partial Responders
Lead sponsor
Providence Health & Services
Phase
Phase 2
Overall status
Recruiting
Start date
March 13, 2024
Completion date
September 15, 2029
Enrollment
28 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma